Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Clinical and economic impact of ibalizumab

<< Previous

Bullboard Posts

Next >>

Comment by Jack1016on Feb 03, 2021 9:42am

63 Views

Post# 32457030

RE:RE:RE:RE:Clinical and economic impact of ibalizumab

Because Trogarzo is good to reduce the virus to undetectable low, I'd expect a much higher five-yr survival.

scarlet1967 wrote: What would you do if you chance for survival would increase with "merely 9%"vs none?

scarlet1967 wrote: I sent it to Leah anyway.

Jack1016 wrote:
The report said: "In the base case, five-year survival increased from 38% with OBR to 47% with IBA+OBR. ..Adding ibalizumab to an OBR increased 5-year survival by 9% compared to OBR alone... IBA+OBR was not cost-effective even with 100% efficacy."

Merely 9% increase? I wonder if Theratechnologies gains updated data.